Plasma Biomarkers for Dementias in the Era of Disease-Modifying Therapies, AD/PD™ Session Spotlight

In episode 2 of AD/PD™ Session Spotlight, we feature Plenary Lecture 3, the Don Price Memorial Lecture, titled "Plasma Biomarkers for Dementias in the Era of Disease-Modifying Therapies," presented by Prof. Charlotte Teunissen (The Netherlands) and chaired by Dr. Sangram Sisodia (USA).

This compelling lecture honors the legacy of Dr. Donald L. Price and explores the transformative role of plasma biomarkers in Alzheimer’s disease care, from diagnosis to personalized treatment strategies.

Key highlights include:

• The clinical readiness of plasma biomarkers like P-tau217 for diagnosing and monitoring Alzheimer’s disease

• Insights from ongoing implementation studies in the Netherlands and international efforts to standardize biomarker use

• The role of biomarkers in predicting treatment response, tracking cognitive change, and identifying molecular subtypes

• Emerging technologies, such as proteomics, and their use in developing predictive biomarker panels

• New frontiers in biomarker discovery, including alpha-synuclein seed aggregation assays and dopamine decarboxylase for detecting co-pathologies

This episode is essential for neurologists, clinical researchers, biomarker scientists, and healthcare professionals aiming to integrate biomarkers into routine dementia care and tailor treatments in the era of disease-modifying therapies.

This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.

The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.

https://adpd.kenes.com/